Tom Brett
@tombrettlab.bsky.social
PhD AAZF ATSF FAHA. Associate Prof of Medicine at WashU, Co-Director BBSB PhD Program, Structural Biology, Molecular Mechanisms of Inflammation, lung disease, Alzheimer's Disease. Girlsdad. Outdoor Enthusiast.
Harrison, whose plasma contained a rare antibody, rolled up his sleeve 1,173 times from 1954 to 2018. The Australian is credited with helping 2.4 million babies and advancing scientific research.
James Harrison, whose blood donations saved over 2 million babies, has died
Harrison, whose plasma contained a rare antibody, rolled up his sleeve 1,173 times from 1954 to 2018. The Australian is credited with helping 2.4 million babies and advancing scientific research.
npr.org
George was a great guy. I vividly remember meeting him at a mixer at the IUCr meeting in Seattle in '97 when I was a grad student. We had an hour long conversation about SHELX and crystallography and other things over beers. Both a deep thinker and down to earth guy. He leaves a big impact.
CCDC Cambridge@ccdc.cam.ac.uk · 2y agoThe CCDC team are saddened to learn that George Sheldrick has passed away. His impact in #Crystallography was immense; from the SHELX software used globally, to teaching, structures, journals, and more. More by the ECA here: ccdc-info.com/41gvV3M
Fun fact about George Sheldrick: he wrote a paper on his SHELX software (that everyone uses for small molecule crystallography) in Acta Cryst A which caused the journal to go from Impact Factor 2 to an IF = 50. Spawned discussion on the relevance of IFs. Huge impact.
ACA: The Structural Science Society@acastructuralsci.bsky.social · 2y agoWe are saddened to hear of the passing of George Sheldrick. A dedicated professional with a distinguished career, his work and leadership touched countless lives. Our hearts go out to his family during this difficult time. Remember George with us: bit.ly/3QtoTUy
Mapping Trem2 ligand interactions by the group who brought us the first Trem2 crystal structure @tombrettlab.bsky.social
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands - Molecular Neurodegeneration
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have bee...
molecularneurodegeneration.biomedcentral.com
Right about now wondering how many Trump voters work at Universities in: Facilities Management Environmental Services Construction/renovation projects (including steel workers, HVAC, electrical, plumbing, painters) Large equipment installation or repair Security IT Need I go on…..
Jen A-Brett@jablab3.bsky.social · 2y agoWait, what????
One of the joys of mentoring is getting a glimpse into your students “outside the lab” life. Got to see the amazing #LNYF25 performance including our amazing undergrad researcher Cynthia Zhi!
I am so thrilled to share our latest collab with @jablab3.bsky.social ! Structural mapping of #TREM2 ligand interactions by #BLI. Led by Jessica Greven; thanks to big contributions by Josh Wydra, Cynthia Zhi,... molecularneurodegeneration.biomedcentral.com/articles/10....
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands - Molecular Neurodegeneration
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have bee...
molecularneurodegeneration.biomedcentral.com
Check out the latest from our groups on TREM2, driven by rockstar postbac Jess Greven and @tombrettlab.bsky.social! @washumedicine.bsky.social doi.org/10.1186/s130...
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer’s disease ligands - Molecular Neurodegeneration
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer’s disease and other neurodegenerative diseases. While a number of TREM2 ligands have bee...
doi.org
As a Minnesota native, I can’t pass up the opportunity for a snow run! Nice storm out there!
You know how the emails pile up over the holidays, and when you clean your inbox out by quick screen/delete, you hope you didn't get rid of something important? Just found out we @jablab3.bsky.social had a big paper accepted a week ago because the notice got deleted. Happy discoveries!
a person is typing on a keyboard with the words deleting delete intensifies
ALT: a person is typing on a keyboard with the words deleting delete intensifies
media.tenor.com
Achievement unlocked! Chestnuts roasted on an open fire! Happy New Year to all!
Had the opportunity tonight to say Hi to my ‘baby blue’
Photo credit in image, I NEED to see this bird that is reportedly in the area.
Ok, finally a science post for BlueSky: Check out our latest editorial in @TheJHLT, strong work as always from Ghandi (@Ghandi_Hassan_ on X) www.sciencedirect.com/science/arti...
Harnessing Mesenchymal Stem Cells for Improving Lung Transplant Outcomes
sciencedirect.com
He doesn’t get it. That’s ok. Fellow karaoke enthusiasts IYKYK ❤️ 🎤
Tracey Thorn@traceythorn.bsky.social · 2y agoBobby Gillespie in today’s Guardian, “I don’t think I’ve ever done karaoke. I hate hearing people murder songs.” 👀
Interesting riff on science inspired by a story about Chappell Roan. I like it. Equally good food for those: 1) quietly struggling to find the motivation to keep going with their science 2) ignorantly raging about the process and taxpayer value of science www.instagram.com/reel/DCjzrMJ...
Some know I have a thing for making playlists, but top 4% worldwide? Ok 🤣 If you wanna check them out Jen AB on @Spotify sites.wustl.edu/jablab (we all know the winner is @Hozier)
We are recruiting for Investigator (Tenure) track faculty @WUSTL in the Dept of Pathology and Immunology; Division of Lab and Genomic Medicine. Official details can be found here: pathology.wustl.edu/wp-content/u...
pathology.wustl.edu
This is very interesting. And it DOES NOT mean that TREM2 is not a good target. It's a complex target.
Shannon Macauley@macauleylab.bsky.social · 2y agoAlector announced that its investigational agent AL002, a TREM2-targeting therapy, did not meet primary, secondary, or exploratory end points in the phase 2 INVOKE-2 trial (NCT04592874) in early AD. company is stopping the long-term extension study.1 www.neurologylive.com/view/al002-f...
